BACTROBAN
LOE ApproachingNDATOPICALOINTMENT
Approved
Dec 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
BACTROBAN by GSK is clinical pharmacology pharmacokinetics following single or repeated intranasal applications of 0. First approved in 1987.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BACTROBAN (mupirocin) is a topical antibiotic ointment that inhibits bacterial protein synthesis by binding to isoleucyl-tRNA synthetase. It is indicated for impetigo and staphylococcal infections, particularly for nasal eradication of methicillin-resistant S. aureus (MRSA) as part of institutional outbreak control programs. The drug demonstrates bactericidal activity at topical concentrations with minimal systemic absorption in adults.
LOE Approaching
Product approaching loss of exclusivity with limited market data publicly available; commercial teams likely focused on defending against generic entry and exploring line extensions.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacokinetics Following single or repeated intranasal applications of 0.2 gram of BACTROBAN NASAL 3 times daily for 3 days to 5 healthy adult male subjects, no evidence of systemic absorption of mupirocin was demonstrated. The dosage regimen used in this study was for…
Worked on BACTROBAN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.